Prelude Capital Management’s Sienna Biopharmaceuticals, Inc. SNNA Stock Holding History

Prelude Capital Management’s Portfolio SNNA Stock Details SNNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-24,516	Closed	-$372K	–	2190
2018 Q2	$372K	Buy	+24,516	New	+$416K	0.02%	612
2018 Q1	–	Sell	-13,974	Closed	-$254K	–	1838
2017 Q4	$254K	Sell	13,974 -7,215	-34%	-$153K	0.02%	564
2017 Q3	$471K	Buy	+21,189	New	+$465K	0.04%	396

Other funds holding SNNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

CCP

Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's SNNA Position: Q3 2018 in Review

Prelude Capital Management sold out of Sienna Biopharmaceuticals, Inc. (SNNA) in Q3 2018, closing a stake of 24,516 shares — an estimated $372K sold.

Prelude Capital Management first reported a position in SNNA in Q3 2017 and held it in 3 quarters. The position peaked at $471K in Q3 2017. 54 funds tracked by Wall St. Rank hold SNNA as of Q3 2018.

Prelude Capital Management reported no remaining Sienna Biopharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Prelude Capital Management sold 24,516 Sienna Biopharmaceuticals, Inc. shares in Q3 2018, an estimated $372K.
Prelude Capital Management first reported a position in Sienna Biopharmaceuticals, Inc. in Q3 2017 and held it in 3 quarters.
Prelude Capital Management's Sienna Biopharmaceuticals, Inc. position peaked at $471K in Q3 2017.
54 funds tracked by Wall St. Rank held Sienna Biopharmaceuticals, Inc. as of Q3 2018.

Based on Prelude Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.